Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2023-10-25 Major Shareholding Noti…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Disclosure of shareholding
Major Shareholding Notification Classification · 99% confidence The document is titled 'Disclosure of shareholding' and explicitly details the shareholding percentages of Rasmussengruppen before and after a recent Private Placement. It mentions specific share counts and the resulting percentage change, referencing the Norwegian Securities Trading Act. This content directly relates to changes in significant share ownership levels crossing reporting thresholds (10% threshold mentioned). This aligns perfectly with the definition for Major Shareholding Notification (MRQ). The document is short and is a direct disclosure, not an announcement of a larger report.
2023-10-25 English
Disclosure of shareholding
Major Shareholding Notification Classification · 98% confidence The document is titled "Disclosure of shareholding" and explicitly details changes in the shareholding percentage of an insider (Jan Haudemann-Andersen and controlled companies, including Datum Opportunity AS) relative to the company's registered share capital. It mentions crossing disclosure thresholds (5% and 10%) and references the Norwegian Securities Trading Act. This directly corresponds to the definition of Director's Dealing (DIRS) or, more broadly, Major Shareholding Notification (MRQ). Since the focus is on an individual/related party's transaction/holding change crossing a threshold, MRQ (Major Shareholding Notification) is the most precise fit, as DIRS usually refers to executive compensation reports or specific director trades, whereas MRQ covers significant ownership changes reported to the exchange. Given the context of crossing disclosure thresholds due to a transaction (lending shares for a private placement settlement), MRQ is the appropriate classification.
2023-10-25 English
Nykode Therapeutics ASA – Share Lending by Closely Associated Parties of a Primary Insider
Director's Dealing Classification · 100% confidence The document details transactions involving shares of Nykode Therapeutics ASA by a person closely associated with a board member (Harald Arnet). Specifically, it reports 'Share lending for settlement in private placement' for a significant volume of shares (26,000,000 and 3,549,400) by entities associated with the insider. This structure—reporting personal share transactions by directors or closely associated persons—is the defining characteristic of a Director's Dealing report, which corresponds to the code DIRS.
2023-10-25 English
Nykode Therapeutics ASA – Share Lending by Closely Associated Parties of a Primary Insider
Regulatory Filings Classification · 99% confidence The document is a formal announcement titled "Nykode Therapeutics ASA – Share Lending by Closely Associated Parties of a Primary Insider." It references a prior stock exchange notice about a private placement and explicitly states, "Please see the attached forms for information regarding share lending by closely related parties of a primary insider in connection with the Private Placement." This content strongly suggests a disclosure related to insider transactions or share dealings following a capital event. The key phrases are 'Share Lending by Closely Associated Parties of a Primary Insider' and the context of a recent share placement. This aligns best with the 'Director's Dealing' category (DIRS), which covers personal share transactions by directors and executives (insider trades), even if this specific instance is share lending by associated parties related to a placement. Since it is an announcement detailing insider activity, DIRS is the most appropriate specific code. It is not a general regulatory filing (RNS) because it fits a more specific category, nor is it a general earnings release (ER) or capital update (CAP), although it relates to a placement.
2023-10-25 English
Nykode Therapeutics ASA – Key Information Regarding Subsequent Offering
Share Issue/Capital Change Classification · 99% confidence The document is titled 'Nykode Therapeutics ASA – Key Information Regarding Subsequent Offering' and details the terms of a subsequent offering of new shares following a private placement. It specifies the subscription price, maximum number of shares, and dates related to the offering process. This activity directly relates to the company raising capital or changing its capital structure through the issuance of new shares. Therefore, it fits the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific financing event.
2023-10-24 English
Nykode Therapeutics ASA - Private Placement Completed
Capital/Financing Update Classification · 98% confidence The document explicitly announces the successful completion of a 'Private Placement' of new shares, raising NOK 505 million. This action involves the issuance of new shares to raise capital and changes the company's capital structure. This directly aligns with the definition of 'Capital/Financing Update' (CAP). While it involves shares, it is a specific financing event rather than a general share repurchase (POS) or a general share issue announcement (SHA), making CAP the most precise fit for a private placement raising significant funds. The document is a formal announcement, not a short notice about a report, so RPA/RNS is less appropriate.
2023-10-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.